Howard Mak
Overview
Explore the profile of Howard Mak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buckley M, Arainga M, Maiorino L, Pires I, Kim B, Michaels K, et al.
Mol Ther
. 2025 Jan;
33(3):1105-1117.
PMID: 39797396
mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate...
2.
Kanelli M, Bardhan N, Sarmadi M, Eshaghi B, Alsaiari S, Rothwell W, et al.
ACS Nano
. 2024 Oct;
18(44):30433-30447.
PMID: 39462900
Multimodal cancer therapies are often required for progressive cancers due to the high persistence and mortality of the disease and the negative systemic side effects of traditional therapeutic methods. Thus,...
3.
Frose J, Rowley J, Salehi Farid A, Rakhshandehroo T, Leclerc P, Mak H, et al.
Sci Adv
. 2024 Sep;
10(38):eadn3816.
PMID: 39292778
CAR T cell therapy has revolutionized the treatment of a spectrum of blood-related malignancies. However, treatment responses vary among cancer types and patients. Accurate monitoring of CAR T cell dynamics...
4.
Buckley M, Arainga M, Maiorino L, Pires I, Kim B, Michaels K, et al.
bioRxiv
. 2024 Jul;
PMID: 38979236
mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate...
5.
Kanelli M, Bardhan N, Sarmadi M, Alsaiari S, Rothwell W, Pardeshi A, et al.
bioRxiv
. 2023 Apr;
PMID: 37090507
Graphical Abstract:
6.
Momin N, Palmeri J, Lutz E, Jailkhani N, Mak H, Tabet A, et al.
Nat Commun
. 2022 Jan;
13(1):109.
PMID: 35013154
Direct injection of therapies into tumors has emerged as an administration route capable of achieving high local drug exposure and strong anti-tumor response. A diverse array of immune agonists ranging...
7.
Hao L, Rohani N, Zhao R, Pulver E, Mak H, Kelada O, et al.
Nat Mater
. 2021 Jul;
20(10):1440-1448.
PMID: 34267368
Therapeutic outcomes in oncology may be aided by precision diagnostics that offer early detection, localization and the opportunity to monitor response to therapy. Here, we report a multimodal nanosensor engineered...
8.
Jailkhani N, Ingram J, Rashidian M, Rickelt S, Tian C, Mak H, et al.
Proc Natl Acad Sci U S A
. 2019 May;
116(28):14181-14190.
PMID: 31068469
Extracellular matrix (ECM) deposition is a hallmark of many diseases, including cancer and fibroses. To exploit the ECM as an imaging and therapeutic target, we developed alpaca-derived libraries of "nanobodies"...
9.
Ghosh J, Nguyen A, Bigelow C, Poor S, Qiu Y, Rangaswamy N, et al.
Nat Commun
. 2017 Mar;
8:14837.
PMID: 28332616
Protein drugs that neutralize vascular endothelial growth factor (VEGF), such as aflibercept or ranibizumab, rescue vision in patients with retinal vascular diseases. Nonetheless, optimal visual outcomes require intraocular injections as...